71 related articles for article (PubMed ID: 3491956)
1. Therapeutic possibilities of virus-modified tumor cell extracts and interleukin-2 in human ovarian cancer.
Lotzová E
Nat Immun Cell Growth Regul; 1986; 5(6):277-82. PubMed ID: 3491956
[No Abstract] [Full Text] [Related]
2. [Effects of human interleukin-2 gene transfer on the immunity of ovarian cancer cell line SKOV3].
Zhang Z; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2000 Jul; 35(7):427-9. PubMed ID: 11776192
[TBL] [Abstract][Full Text] [Related]
3. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
4. [Effects of interleukin-2 and lymphokine-activated killer cells on cell cultures and on transplanted tumors (nude mouse) of human pancreatic carcinomas].
Kühl JS; Klapdor R; Bahlo M; Arps H; Dietel M; Mohr M
Beitr Infusionther Klin Ernahr; 1987; 18():261-5. PubMed ID: 3501948
[No Abstract] [Full Text] [Related]
5. Immunologic control of ovarian cancer.
Zighelboim J; Nio Y; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1988; 7(4):216-25. PubMed ID: 3070371
[No Abstract] [Full Text] [Related]
6. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
7. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
8. Natural immunity against ovarian tumors.
Lotzová E; Savary CA; Freedman R; Bowen JM
Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):269-75. PubMed ID: 3491727
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
10. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
[TBL] [Abstract][Full Text] [Related]
11. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
12. Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector.
Koppold B; Sauer G; Büning H; Hallek M; Kreienberg R; Deissler H; Kurzeder C
Int J Oncol; 2005 Jan; 26(1):95-101. PubMed ID: 15586229
[TBL] [Abstract][Full Text] [Related]
13. [Natural killer (NK) cell activity in the peripheral blood of patients with malignant diseases: melanoma, carcinoma, chronic and acute lymphatic leukemia].
Gabrilovac J
Lijec Vjesn; 1985 Aug; 107(8):323-6. PubMed ID: 3864002
[No Abstract] [Full Text] [Related]
14. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
15. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
[TBL] [Abstract][Full Text] [Related]
16. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
17. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.
Carlsten M; Björkström NK; Norell H; Bryceson Y; van Hall T; Baumann BC; Hanson M; Schedvins K; Kiessling R; Ljunggren HG; Malmberg KJ
Cancer Res; 2007 Feb; 67(3):1317-25. PubMed ID: 17283169
[TBL] [Abstract][Full Text] [Related]
18. [Study on the TIL and NK of IL-2 injected via pelvic retroperitoneal space in gynecological cancer patient].
Chen J; Cao ZY; Zhang P; Peng ZL; Yang YL; Bi JH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):406-8. PubMed ID: 15181850
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
Leveque L; Deknuydt F; Bioley G; Old LJ; Matsuzaki J; Odunsi K; Ayyoub M; Valmori D
J Immunother; 2009; 32(2):101-8. PubMed ID: 19238008
[TBL] [Abstract][Full Text] [Related]
20. CA125 measurement in epithelial ovarian cancer: a 10-year anniversary of clinical investigation.
Berkowitz RS
Gynecol Oncol; 1993 Apr; 49(1):1-2. PubMed ID: 8482551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
